Loading…
Loading…
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has engaged Dr. Reuter Investor Relations (" Dr. Reuter ") to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026. Dr. Reuter is a recognized European investor relations and financial communications firm with an established network of institutional investors, retail shareholders, and financial media throughout the DACH region and the European Union. The engagement is intended to enhance the Company's visibility among European investors, support market education regarding its clinical research strategy, and strengthen shareholder communications. Dr. Reuter's business address is Tower 185, Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt, Germany, and the firm may be contacted at e.reuter@dr-reuter.eu .
The addition of leading AI researcher further strengthens SciSparc's scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA
SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera's issued and outstanding common shares following the financing
T oronto, Ontario – TheNewswire - August 17, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed the final tranche (the “ Final Tranche ”) of its non-brokered private placement (the “ Offering ”), as previously announced on June 30, 2026, July 2, 2026 and August 12, 2026. Under the Final Tranche, the Company raised C$2,700,000 from the sale of 22,500,000 units (each, a “ Unit ”) at C$0.12 per Unit. Each Unit is comprised of one common share in the capital of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Unit Warrant ”). Each Unit Warrant entitles the holder to purchase one Common Share at an exercise price of US$0.115 per Common Share, equivalent to C$0.16 per Common Share, until August 17, 2029. The Unit Warrants are also subject to an acceleration provision whereby, upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, the Company will accelerate the expiry date of 50% of the unexercised Unit Warrants and provide three business days' advance written notice to holders thereof of such accelerated expiry date. The Unit Warrants are non-transferable.
Toronto, Ontario – August 12, 2026 – TheNewswire - NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed the first tranche (the “ First Tranche ”) of its non-brokered private placement (the “ Offering ”), as previously announced on June 30, 2026 and July 2, 2026. Under the First Tranche, the Company raised C$2,700,000 from the sale of 22,500,000 units (each, a “ Unit ”) at C$0.12 per Unit. Each Unit is comprised of one common share in the capital of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Unit Warrant ”). Each Unit Warrant entitles the holder to purchase one Common Share for US$0.115 per Common Share, equivalent to C$0.16 per Common Share, until August 1 2 , 2029. The Unit Warrants will also have an acceleration provision whereby upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, the Company will accelerate the expiry date of 50% of the unexercised Unit Warrants and provide three (3) business days' advance written notice to holders thereof of such accelerated expiry date. The Unit Warrants are non-transferable.
TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroThera's pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.”
Toronto, Ontario – TheNewswire - A ugust 12 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that the Japanese Patent Office has granted the company a patent for its pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. NeuroThera believes this synergistic approach may enable lower effective dosing while helping to mitigate dose ‑ related side ‑ effect concerns associated with established treatments.